

# Building bridges between drug regulation, HTA and clinical guidelines

M.A. Hogervorst  
 Mathias Møllebæk, Rick A. Vreman,  
 Junfeng Wang, Aukje K.  
 Mantel-Teeuwisse, Wim G. Goettsch

## OBJECTIVES

This study discusses tangible ways to improve synergies among regulatory, HTA and clinical guideline development processes. The aim was to discover how convergence of evidentiary needs among stakeholders may be achieved, and to identify to which extent converge can be achieved.



## METHODS

Eight online dual moderator (mini) focus groups were organized, contextualised within the case studies diabetes mellitus (DM), head and neck cancer (HN), multiple sclerosis (MS) and myelodysplastic syndromes (MDS). Forty-two experienced (over 10 years) regulators, HTA representatives and clinical guideline developers participated.


## RESULTS

### Four of The Major Themes Highlighted

### All Themes Discussed By Participants in Focus Groups



### Linkage Between These Four Themes



## CONCLUSION

Improving synergy always involves trade-offs, it is key is to find the right balance between the identified strategies